Therapeutical Dose to Thyroid Remnants Determination for Low-risk Thyroid Carcinoma Patient Treated with rhTSH and 1.1 GBq 131I

被引：0
|
作者：
Solny, P. [1 ,2 ,3 ]
Kracmerova, T. [1 ,2 ,3 ]
Jonasova, L. [2 ,3 ]
Vlcek, P. [2 ,3 ]
机构：
[1] Czech Tech Univ, Dept Dosimetry & Applicat Ionizing Radiat, Fac Nucl Sci & Phys Engn, Prague, Czech Republic
[2] Charles Univ Prague, Dept Nucl Med & Endocrinol, Fac Med 2, Prague, Czech Republic
[3] Motol Univ Hosp, Prague, Czech Republic
来源：
RADIOTHERAPY AND ONCOLOGY | 2016年 / 118卷
关键词：
dosimetry; iodine therapy; 1.1; GBq;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
199
引用
收藏
页码：S97 / S97
页数：1
相关论文
共 50 条
  • [31] 131I thyroid uptake in patients treated with 131I-Lipiodol for hepatocellular carcinoma
    Michel Toubeau
    Claude Touzery
    Alina Berriolo-Riedinger
    Alexandre Cochet
    François Brunotte
    Laurent Bedenne
    Jean-Pierre Cercueil
    Denis Krause
    European Journal of Nuclear Medicine, 2001, 28 : 669 - 670
  • [32] Ablation of thyroid remnants with a fixed dose of 7.4 GBq (200 mCi) iodine-131 in differentiated thyroid carcinoma after total thyroidectomy
    Vinken, Maarten
    Oyen, Wim
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50
  • [33] Radiation dose to the testes after 131I therapy for ablation of postsurgical thyroid remnants in patients with differentiated thyroid cancer
    Ceccarelli, C
    Battisti, P
    Gasperi, M
    Fantuzzi, E
    Pacini, F
    Gualdrini, G
    Pierantoni, MC
    Luciani, A
    Djokich, D
    Pinchera, A
    JOURNAL OF NUCLEAR MEDICINE, 1999, 40 (10) : 1716 - 1721
  • [34] Does remnants from low-risk differentiated thyroid cancer patients really be not treated with Iodine-131?
    Barbato, F.
    Capacchione, D.
    Nappi, A.
    Telesca, D.
    Tempone, A.
    Casolino, E.
    Nardelli, A.
    Castaldi, E.
    Ortosecco, G.
    Storto, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 : S321 - S321
  • [35] Thyroid ablation with 1.1GBq (30mCi) iodine-131 with patients with papillary thyroid carcinoma at intermediate risk for recurrence
    Bez, I. H.
    Somai, M.
    Bennour, S.
    Slim, I.
    Ben Slimene, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S788 - S789
  • [36] Changes of dose equivalent rate in vitro in patients with differentiated thyroid carcinoma after 131I remnant ablation after injection of rHTSH
    Wu, Yuping
    Zhang, Xiaoyu
    Lu, Keyi
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62
  • [37] Cytogenetic and dosimetric effects of 131I in patients with differentiated thyroid carcinoma: comparison between stimulation with rhTSH and thyroid hormone withdrawal treatments
    Márcia Augusta da Silva
    Flávia Gomes Silva Valgôde
    Júlia Armiliato Gonzalez
    Hélio Yoriyaz
    Maria Inês Calil Cury Guimarães
    Maria Teresa Carvalho Pinto Ribela
    Carlos Alberto Buchpiguel
    Paolo Bartolini
    Kayo Okazaki
    Radiation and Environmental Biophysics, 2016, 55 : 317 - 328
  • [38] Cytogenetic and dosimetric effects of 131I in patients with differentiated thyroid carcinoma: comparison between stimulation with rhTSH and thyroid hormone withdrawal treatments
    da Silva, Marcia Augusta
    Silva Valgode, Flavia Gomes
    Gonzalez, Julia Armiliato
    Yoriyaz, Helio
    Calil Cury Guimaraes, Maria Ines
    Carvalho Pinto Ribela, Maria Teresa
    Buchpiguel, Carlos Alberto
    Bartolini, Paolo
    Okazaki, Kayo
    RADIATION AND ENVIRONMENTAL BIOPHYSICS, 2016, 55 (03) : 317 - 328
  • [39] LETTER TO THE EDITOR: THYROGLOBULIN-GUIDED 131I ABLATION IN LOW-RISK DIFFERENTIATED THYROID CARCINOMA: IS THE YARDSTICK ACCURATE ENOUGH?
    Giovanella, Luca
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2011, 33 (09): : 1379 - 1380
  • [40] Could the treatment of differentiated thyroid carcinoma with 3.7 and 5.55 GBq of (131I)NaI, on an outpatient basis, be safe?
    de Amorim de Carvalho, Jose Willegaignon
    Sapienza, Marcelo
    Ono, Carla
    Watanabe, Tomoco
    Guimaraes, Maria Ines
    Gutterres, Ricardo
    Marechal, Maria Helena
    Buchpiguel, Carlos
    NUCLEAR MEDICINE COMMUNICATIONS, 2009, 30 (07) : 533 - 541
12345